Stable mixed chimerism and tolerance of vascularized composite allografts via BCL-2 inhibition
Ended Project Grant Awarded Last action
- Award ID
- W81XWH2210958
- Recipient
-
The General Hospital Corporation UEI FLJ7DQKLL226 Part of Partners Healthcare System Incorporated
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $204,480
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date
- Place of performance
- Boston, MA 02114, USA
Award details come from USAspending.gov.
About this award
The Department of the Army Medical Command awarded a $204,480 Project Grant to the Massachusetts General Hospital through the Military Medical Research and Development program. The grant will fund research into stable mixed chimerism and tolerance of vascularized composite allografts via BCL-2 inhibition from September 30, 2022 through August 31, 2025.
The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of improving military and public health outcomes. This award will allow the Massachusetts General Hospital to investigate methods for promoting allograft tolerance without immunosuppression through the inhibition of BCL-2, which could enable transplantation of vascularized tissues and help address health issues for service members and civilians alike.
Quick answers
Who received award W81XWH2210958?
W81XWH2210958 was awarded to The General Hospital Corporation by Medical Command (Department of the Army) on September 30, 2022.
How much is award W81XWH2210958 worth?
$204,480 has been obligated on W81XWH2210958.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award